Eyestem presented interim Eyecyte-RPE Phase 2 data at EURetina 2026 in Vienna. The data show continuing visual acuity gains in geographic atrophy, an excellent safety profile, and a US IND filing planned for early 2027.
India is transitioning from a global manufacturing hub to a leader in deeptech innovation. In this featured interview, Dr. Jogin Desai, CEO of Eyestem, explores how a compressed therapy timeline, the ₹10,000 crore Biopharma SHAKTI programme, and a focus on “reversing” rather than just “slowing” diseases are positioning India to deliver life-changing medical solutions to the world at a fraction of the traditional cost.
India’s Eyestem Research advances to Phase 2 clinical trials for Eyecyte-RPE™ following stellar Phase 1 results that showed significant vision restoration. As a scalable “off-the-shelf” solution for dry AMD, this therapy represents a major leap in regenerative medicine and a potential global cure for Geographic Atrophy.
Dr. Jogin Desai presents Eyecyte-RPE™ data at Innoxbio CGT 2025 in China, showing a 14.8-letter average gain in visual acuity and a strong safety profile.
Eyestem Research has successfully closed an oversubscribed funding round, securing $10 million to accelerate the development of Eyecyte-RPE™, its investigational cell therapy for dry age-related macular degeneration (dry AMD).
Eyestem’s new cell therapy for Dry AMD, showing promising safety and vision improvement in Phase 1 trials. A new hope for treating geographic atrophy.
All nine subjects of phase 1 injected without any serious adverse events.
